Results 91 to 100 of about 59,358 (257)

Silent Sinus Syndrome: 13‐Year Experience With Endoscopic Surgery and Long‐Term Patient Outcomes

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objectives Silent sinus syndrome (SSS) is a rare condition characterized by spontaneous maxillary sinus collapse with associated orbital deformity. Existing studies are limited by heterogeneous surgical approaches, small sample sizes, and short follow‐up.
Sholem Hack, Arkadi Yakirevitch, Gabriel Nakache, Eran Glikson   +3 more
wiley   +1 more source

Online public concern about allergic rhinitis and its association with COVID-19 and air quality in China: an informative epidemiological study using Baidu index

BMC Public Health
Background Allergic rhinitis is a common health concern that affects quality of life. This study aims to examine the online search trends of allergic rhinitis in China before and after the COVID-19 epidemic and to explore the association between the ...
Yi Yu, Qinzhun Zhang, Xinmeng Yao, Jinghua Wu, Jialu He, Yinan He, Huaqiang Jiang, Dongxin Lu, Chengyin Ye   +8 more
doaj   +1 more source

Enhanced Early Detection of Allergic Rhinitis: A Prospective Study on a Symptom‐Based Predictive Model

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Introduction Allergic rhinitis (AR) and non‐allergic rhinitis (NAR) share overlapping symptoms but differ in pathophysiology and treatment. Current AR diagnosis relies on skin prick testing (SPT) and serum IgE quantification, both of which are complex.
Ke‐Zhang Zhu, Chao He, Si‐Zhe Zhu, Zheng Liu, Ming Zeng   +4 more
wiley   +1 more source

Association of Cat Sensitization With Comorbid Asthma in Patients With Allergic Rhinitis: A Real‐World Study

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background The prevalence of allergic rhinitis (AR) and asthma (AS) comorbidity (AR + AS) is increasing and is associated with severe allergic symptoms. The impact of cat dander sensitization on AR + AS remains unclear. Methods In this retrospective study, 1154 patients with AR alone and 213 patients with AR + AS were enrolled at the Third ...
Wei‐Hao Wang, Xin Luo, Zhen‐Hao Xiao, Hong‐Kai Wang, Ya‐Na Zhang, Qin‐Tai Yang   +5 more
wiley   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source

5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study

Journal of Asthma and Allergy, 2013
Elide Anna Pastorello,1 Laura Losappio,1 Stefania Milani,2 Giuseppina Manzotti,3 Valentina Fanelli,4 Valerio Pravettoni,5 Fabio Agostinis,6 Alberto Flores D’Arcais,7 Ilaria Dell'Albani,8 Paola Puccinelli,9 Cristoforo Incorvaia,10 Franco ...
Pastorello EA, Losappio L, Milani S, Manzotti G, Fanelli V, Pravettoni V, Agostinis F, D'Arcais AF, Dell'Albani I, Puccinelli P, Incorvaia C, Frati F   +11 more
doaj  

Aspects of the pathogenesis, diagnosis, and treatment of allergic rhinitis

Каразінський імунологічний журнал
Background. Allergic rhinitis is one of the most common diseases worldwide. This article reviews current concepts of the pathogenesis, diagnosis, and treatment of allergic rhinitis, enabling an individualized approach to patients with this condition ...
A.O. Dushyk
doaj   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Art v 1 and Amb a 4 Co‐Sensitization Identifies Italian Patients at Risk for Mugwort‐Celery‐Spice Syndrome

Allergy, EarlyView.
Three molecular profiles identified among Art v 1/Amb a 4‐sensitized patients: Art v 1 monosensitization, Amb a 4 monosensitization, and dual sensitization to both allergens. Art v 1 monosensitization was predominantly associated with allergic rhinitis, reflecting a classical airborne allergy pattern.
Enrico Scala, Gabriella Cusa, Valeria Villella, Damiano Abeni, Mauro Giani, Emma Cristina Guerra, Maria Locanto, Giorgia Meneguzzi, Lia Pirrotta, Donato Quaratino, Alessandra Zaffiro, Elisabetta Caprini, Maria Barrale, Ignazio Brusca, Valerio Pravettoni, Lorenzo Cecchi, Danilo Villalta, Martina Aumayr, Irene Mittermann, Christian Lupinek, Riccardo Asero   +20 more
wiley   +1 more source

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

Allergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier, Z. Abdul Hameed Ansari, A. H. Abdul Latiff, M. M. Abuzakouk, M. S. Agcaoili‐De Jesus, R. C. Agondi, M. Al‐Ahmad, A. A. Alangari, H. Alhameli, C. D. Alonso Bello, S. Alshareef, S. Al‐Tamemi, S. Altrichter, H. Al Wahshi, S. Aquilina, M. Araújo, R. Arnaout, R. Asero, B. Ballmer‐Weber, C. Bangert, A. Bauer, M. Ben‐Shoshan, J. A. Bernstein, C. Bindslev‐Jensen, M. Bizjak, I. Boccon‐Gibod, H. Bonnekoh, L. Bouillet, K. Brockow, Z. Brzoza, M. Bulatović Ćalasan, A. Bulkhi, T. Buttgereit, A. Bygum, T. Caballero, O. Calderon, R. Campos, M. Cancian, E. Carne, M. A. Castor, I. Cerecedo, T. Çetinarslan, I. Cherrez‐Ojeda, N. Chkhikvadze, H. J. Chong‐Neto, K. Choo, G. Christoff, C.‐Y. Chu, K. Ciupka, N. Conlon, C. Costa, T. Craig, P. Criado, I. Danilycheva, R. Darlenski, E. De Arruda Chaves, L. de Montjoye, M. S. Doutre, A. Du‐Thanh, D. Ebo, S. Elkhalifa, S. Elmariah, T. El‐Shanawany, L. F. Ensina, R. Ertaş, R. Fachini Jardim Criado, M. Ferrer, S. Ferrucci, J. S. Fok, D. Fomina, L. Fonacier, G. Fouda, I. Francescantonio, A. Fukunaga, C. A. Galvan Calle, E. Garcia, K. Gáspár, A. Gelincik, S. Geng, K. Godse, M. Gonçalo, M. Gotua, C. Grattan, M. Grosber, G. Guidos Fogelbach, M. Guilarte, R. Guillod, E. Hamelmann, J. Hawkes, K. Hayama, R. Heuer, M. Hide, W. Hoetzenecker, N. Inomata, H.‐R. Kang, A. Kaplan, A. Kapp, M. Karam, A. Kasperska‐Zajac, C. H. Katelaris, A. Kessel, M. Khoshkhui, B. Kim, T. Kinaciyan, E. Kocatürk, M. Kolacinska‐Flont, P. Kolkhir, G. N. Konstantinou, M. Kosnik, D. Krasowska, K. Kulthanan, M. S. Kumaran, I. Kuprys‐Lipinska, M. Labrador, J. I. Larco, D. Larenas‐Linnemann, E. Latysheva, E. Lazaridou, P. H. Li, H. Lima, U. Lippert, M. Magerl, M. Makris, J. Alves Marcelino, A. V. Marzano, I. Medina, R. Meshkova, D. Micallef, R. Mohammed Ali, C. G. Mortz, M. Munoz, H. N. G. Oude Elberink, A. Nakonechna, I. Nasr, A. Nast, E. Netchiporouk, E. Nettis, S. Nieto, I. Ogueta Canales, T.‐L. Okas, R. L. Orfali, E. Özkaya, C. Parisi, A. Pennitz, R. Pawankar, M. P. Pereira, J. Peter, E. Petkova, P. D. Pigatto, I. Podder, T. Popov, G. Porebski, P. Pyatilova, G. D. Ramon, H. A. Ratti Sisa, M. Recto, K. Ress, K. Ridge, M. Riedl, C. Ritchie, N. Rosario Filho, I. Rosmaninho, M. Rudenko, M. Rukhadze, K. Rutkowski, V. Sabato, U. M. Sahiner, S. Saini, F. Saleh Al Sabbagh, A. Salman, F. Salvo, J. Sanchez, A. Santucci, S. Schliemann, P. Schmid‐Grendelmeier, B. E. Sekerel, F. Serpa, F. Sheikh, J. Sheikh, H. Shendi, F. Siebenhaar, M. Sonomjamts, A. Soria, B. Sousa Pinto, M. Staevska, P. Staubach, M. Stephan, K. Stevanovic, L. Stingeni, M. Stobiecki, Ö. Su Küçük, G. Sussman, A. Szegedi, S. Takahagi, A. Tanaka, N. Teovska Mitrevska, S. F. Thomsen, E. Toubi, F. Tsatsou, M. Turk, Z. Vadasz, A. Valerieva, S. Valle, M. v. Doorn, B. Veleiro Perez, C. E. Vera Ayala, C. Vestergaard, R. J. Vieira, C. W. Maruta, B. Wedi, R. N. Werner, E. W. Y. Yap, P. Xepapadaki, Y. Xiang, Y.‐M. Ye, P. Yong, G. Yosipovitch, A. Z. J. Zalewska‐Janowska, C. Zeyen, Z. Zhao, M. Metz, A. M. Giménez‐Arnau   +221 more
wiley   +1 more source